Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, U.S.A.
Biochem Soc Trans. 2023 Jun 28;51(3):1191-1199. doi: 10.1042/BST20221347.
RAS proteins are small GTPases that transduce signals from membrane receptors to signaling pathways that regulate growth and differentiation. Four RAS proteins are encoded by three genes - HRAS, KRAS, NRAS. Among them, KRAS is mutated in human cancer more frequently than any other oncogene. The KRAS pre-mRNA is alternatively spliced to generate two transcripts, KRAS4A and KRAS4B, that encode distinct proto-oncoproteins that differ almost exclusively in their C-terminal hypervariable regions (HVRs) that controls subcellular trafficking and membrane association. The KRAS4A isoform arose 475 million years ago in jawed vertebrates and has persisted in all vertebrates ever since, strongly suggesting non-overlapping functions of the splice variants. Because KRAS4B is expressed at higher levels in most tissues, it has been considered the principal KRAS isoform. However, emerging evidence for KRAS4A expression in tumors and splice variant-specific interactions and functions have sparked interest in this gene product. Among these findings, the KRAS4A-specific regulation of hexokinase I is a stark example. The aim of this mini-review is to provide an overview of the origin and differential functions of the two splice variants of KRAS.
RAS 蛋白是一种小的 GTP 酶,可将信号从膜受体转导至调节生长和分化的信号通路。三种基因 HRAS、KRAS、NRAS 编码四种 RAS 蛋白。其中,KRAS 的突变在人类癌症中比任何其他癌基因都更频繁。KRAS 前体 mRNA 选择性剪接产生两种转录本,KRAS4A 和 KRAS4B,它们编码不同的原癌蛋白,几乎只在其 C 末端的高变区(HVR)中不同,该区域控制细胞内运输和膜结合。KRAS4A 异构体在 4.75 亿年前出现在有颌脊椎动物中,此后一直存在于所有脊椎动物中,强烈表明剪接变体具有非重叠的功能。由于 KRAS4B 在大多数组织中的表达水平更高,因此它被认为是主要的 KRAS 异构体。然而,越来越多的证据表明 KRAS4A 在肿瘤中的表达以及剪接变体特异性相互作用和功能,这引起了人们对该基因产物的兴趣。在这些发现中,KRAS4A 对己糖激酶 I 的特异性调节是一个明显的例子。本综述的目的是概述 KRAS 两种剪接变体的起源和差异功能。